目的 觀察燈盞生脈膠囊聯(lián)合左西孟旦注射液治療慢性心力衰竭的臨床療效。方法 選取2019年1月—2021年3月在新鄉(xiāng)市第一人民醫(yī)院接受治療的102例慢性心力衰竭患者，將患者根據(jù)隨機(jī)數(shù)字表法分為對(duì)照組和治療組，每組各51例。對(duì)照組給予左西孟旦注射液，起始靜脈注射負(fù)荷量為12 μg/kg，之后靜脈滴注0.15～0.20μg/(kg∙min)，1次/周。治療組在對(duì)照組治療的基礎(chǔ)上口服燈盞生脈膠囊，2粒/次，3次/d。兩組均連續(xù)治療4周。觀察兩組的臨床療效，比較兩組的心功能指標(biāo)、血清因子水平。結(jié)果 治療后，治療組總有效率為92.16%，高于對(duì)照組的總有效率70.59%（P＜0.05）。治療后，兩組左心室舒張末期內(nèi)徑（LVEDD）、左心室收縮末期容積（LVESV）、左心室收縮末期內(nèi)徑（LVESD）均顯著降低，左室射血分?jǐn)?shù)（LVEF）、心指數(shù)（CI）顯著升高（P＜0.05），且治療組LVEDD、LVESV、LVESD低于對(duì)照組，LVEF、CI高于對(duì)照組（P＜0.05）。治療后，兩組血清C反應(yīng)蛋白（CRP）、腫瘤壞死因子-α（TNF-α）、白細(xì)胞介素-6（IL-6）、N末端B型鈉尿肽原（NT-proBNP）、肌鈣蛋白T（cTnT）水平較治療前顯著降低（P＜0.05），且治療組血清CRP、TNF-α、IL-6、NT-proBNP、cTnT水平明顯低于對(duì)照組（P＜0.05）。結(jié)論 燈盞生脈膠囊聯(lián)合左西孟旦注射液治療慢性心力衰竭療效顯著，可促進(jìn)心功能恢復(fù)，降低血清因子水平，且具有較好的安全性。

Objective To observe the therapeutic effect of Dengzhan Shengmai Capsules combined with Levosimendan Injection in treatment of chronic heart failure. Methods Patients (84 cases) with chronic heart failure in Xinxiang First People's Hospital from January 2019 to March 2021 were randomly divided into control and treatment groups, and each group had 51 cases. Patients in the control group were iv administered with Levosimendan Injection, the initial intravenous load was 12 μg/kg, and followed by intravenous drip of 0.15-0.20 μg/(kg∙min), once weekly. Patients in the treatment group were po administered with Dengzhan Shengmai Capsules on the basis of the control group, 2 grains/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacies were evaluated, and the cardiac function and serum factor level in two groups were compared. Results After treatment, the total effective rate of the treatment group was 92.16%, which was higher than 70.59% of the control group (P < 0.05). After treatment, the LVEDD, LVESV, and LVESD in two groups were significantly decreased, but the LVEF and CI in two groups were significantly increased (P < 0.05). And the LVEDD, LVESV, and LVESD in the treatment group were lower than those in the control group, but the LVEF and CI in the treatment group were higher than those in the control group (P < 0.05). After treatment, the serum levels of CRP, TNF-α, IL-6, NT-proBNP, and cTnT in two groups were significantly lower than those before treatment, and the serum levels of CRP, TNF-α, IL-6, NT-proBNP, and cTnT in the treatment group were significantly lower than those in the control group (P < 0.05). Conclusion Dengzhan Shengmai Capsules combined with Levosimendan Injection has clinical curative effect in treatment of chronic heart failure, can promote the recovery, and reduce the level of serum factors with good safety.

R972

新鄉(xiāng)市科技攻關(guān)計(jì)劃項(xiàng)目(GG2019031)